Innovating Works

CHARLES RIVER DISCOVERY RESEARCH SERVICE...

Desconocido
Maxima Butterfly: From Caterpillar to BUTTERFLY: supporting transformation of DCs in a paediatric oncology network CHARLES RIVER DISCOVERY RESEARCH SERVICES GERMANY GMBH participó en un HORIZON EUROPE: HORIZON-MSCA-2021-COFUND-01 Every year, around 600 children in the Netherlands get cancer and one in four children dies from this illness. More than ten years ago, a gr...
2022-10-10 - 2027-12-31 | Financiado
PERSIST-SEQ: Building a reproducible single cell experimental workflow to capture tumour cell persistence CHARLES RIVER DISCOVERY RESEARCH SERVICES GERMANY GMBH participó en un H2020: H2020-JTI-IMI2-2020-20-two-stage It is the ambition of PRESIST-SEQ to provide a new gold standard in single-cell experimental workflows the cancer research community by deve...
2021-06-28 - 2026-06-30 | Financiado
SECRET: Exploitation of the SECRETory pathway for cancer therapy to address European research CHARLES RIVER DISCOVERY RESEARCH SERVICES GERMANY GMBH participó en un H2020: H2020-MSCA-ITN-2019 Breast and colorectal cancer (BC and CRC) are the most frequent cancers accounting for 19% of all deaths from cancer in Europe. In case of t...
2019-08-09 - 2023-09-30 | Financiado
ITCC-P4: ITCC Pediatric Preclinical POC Platform Sofia ref. 116064 CHARLES RIVER DISCOVERY RESEARCH SERVICES GERMANY GMBH participó en un H2020: H2020-JTI-IMI2-2015-07-two-stage Cancer remains the leading cause of disease-related death in children. For the ~25% of children who experience relapses of their malignant s...
2017-05-18 - 2023-12-31 | Financiado
PREDECT: New Models for Preclinical Evaluation of Drug Efficacy in Common Solid Tumours CHARLES RIVER DISCOVERY RESEARCH SERVICES GERMANY GMBH participó en un FP7: Traditional preclinical discovery methods, particularly for target validation, poorly predict drug efficacy, causing a high attrition rate i...
Financiado
MABTOX: Generation and Evaluation of Next generation Antibody Toxin Conjugates for Cancer Therapy CHARLES RIVER DISCOVERY RESEARCH SERVICES GERMANY GMBH participó en un FP7: Therapeutic antibodies have transformed cancer therapy during the last decade, due to their high selectivity of targeting cancer cells in co...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.